Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

The Effect of CBD on Sleep Quality Following Late Evening Exercise

30 de abril de 2026 actualizado por: KU Leuven
The trial is a double-blind, placebo-controlled crossover design. In a randomized order, 20 participants undergo one control and two experimental sessions separated by a 1-week wash out period. During the no exercise/rest session, participants' sleep is monitored via polysomnography following a rest day. During the training sessions participants' sleep is monitored following a high intensity interval training (HIIT) in the late evening (finishing 1h prior to bedtime). During these sessions participants receive 2x 200mg CBD or placebo in a randomized order.

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Tipo de estudio

Intervencionista

Inscripción (Estimado)

20

Fase

  • Fase 2

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Vlaams-Brabant
      • Leuven, Vlaams-Brabant, Bélgica, 3001
        • Reclutamiento
        • Bakala Athletic Performance Facility
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Adulto

Acepta Voluntarios Saludables

Sí

Descripción

Inclusion Criteria:

  1. Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures
  2. Use of highly effective methods of birth control during the entire trial and for up to 4 months after the last dose of CBD; defined as those that, alone or in combination, result in low failure rate (i.e., less than 1% per year) when used consistently and correctly; such as implants, injectables, combined oral contraceptives, some IUDs, true sexual abstinence (i.e. refraining from heterosexual intercourse during the entire period of risk associated with the Trial treatment(s)) or commitment to a vasectomised partner.
  3. Age between 18-40 years old at the time of signing the Informed Consent Form (ICF)
  4. Recreationally active (between 2-8h/wk)
  5. Good health status confirmed by a sport medical screening
  6. Body fat percentage below 20% (males) or 25% (females) as estimated by a Dual-energy X-ray absorptiometry (DXA) scan
  7. Good sleep efficiency determined by the Pittsburgh Sleep Quality Index (PSQI, score ≤ 4)

Exclusion Criteria:

  1. Self-reported sleep disturbances
  2. Habitual smoking (> 1 occasion/month)
  3. Any kind of injury/incapability that is a contra-indication to perform high intensity interval training
  4. Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using an adequate, highly effective contraceptive. A woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming post menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy.
  5. Participation in another interventional Trial with an investigational medicinal product (IMP) or device
  6. Use of CBD related products 3 months prior to the start of the experimental trial (including CBD oil, cannabis or other substances containing cannabinoids)
  7. Intake of any medication or nutritional supplement that influences sleep quality 3 months prior to the start of the experimental trial
  8. Shift workers or extreme morning and evening chronotypes (scores between 16-30 or 70-86 on the Morningness-Eveningness Questionnaire (MEQ))

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación cruzada
  • Enmascaramiento: Cuadruplicar

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Exercise session 1
Participants perform a late evening exercise and receive placebo/CBD supplements
participants receive 2 x 200mg CBD or placebo
Participants perform a late evening high-intensity interval training (HIIT) ending 1 hour prior to sleep
Experimental: Exercise session 2
Participants perform a late evening exercise and receive placebo/CBD supplements
participants receive 2 x 200mg CBD or placebo
Participants perform a late evening high-intensity interval training (HIIT) ending 1 hour prior to sleep
Experimental: No exercise / rest session
Participants do not perform a late evening exercise and receive placebo/CBD supplements
participants receive 2 x 200mg CBD or placebo

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
sleep efficiency
Periodo de tiempo: Nightly assessment on three specific study nights, separated by 7-day intervals
the primary outcome of the current study is the parameter sleep efficiency (SE = time asleep (min) / time in bed (min)) measured by PSG
Nightly assessment on three specific study nights, separated by 7-day intervals

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Sleep indices (other than sleep efficiency)
Periodo de tiempo: Nightly assessment on three specific study nights, separated by 7-day intervals
These outcomes include sleep period time (SPT), wake after sleep onset (WASO), total sleep time (TST), sleep onset latency (SOL), sleep maintenance efficiency (SME), amount of time in sleep stages (N1, N2, N3, REM, NREM), slow waves, sleep spindles
Nightly assessment on three specific study nights, separated by 7-day intervals
Perceived sleep quality
Periodo de tiempo: Assessment on three specific study mornings, separated by 7-day intervals
Participants complete the St. Mary's Hospital questionnaire to evaluate their subjective sleep quality from the previous night
Assessment on three specific study mornings, separated by 7-day intervals
Circulating hormones involved in sleep and stress
Periodo de tiempo: Assessment on three specific study nights, separated by 7-day intervals
Circulating hormones such as growth hormone, melatonin and cortisol are measured
Assessment on three specific study nights, separated by 7-day intervals
Plasma and urinary catecholamines (adrenaline, noradrenaline, dopamine) and serotonin concentration
Periodo de tiempo: Assessment on three specific study nights, separated by 7-day intervals
Plasma catecholamines (adrenaline, noradrenaline, dopamine) and serotonin concentration is measured in blood samples collected 30 minutes prior to sleep, and in urine samples collected during the night.
Assessment on three specific study nights, separated by 7-day intervals

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

19 de marzo de 2026

Finalización primaria (Estimado)

31 de mayo de 2026

Finalización del estudio (Estimado)

7 de junio de 2026

Fechas de registro del estudio

Enviado por primera vez

30 de abril de 2026

Primero enviado que cumplió con los criterios de control de calidad

30 de abril de 2026

Publicado por primera vez (Actual)

6 de mayo de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

6 de mayo de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

30 de abril de 2026

Última verificación

1 de abril de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir